Plasma Osteopontin Correlates with Glycemic Control in Type 2 Diabetes Mellitus Patients

Maria Diah Pramudianti, Briggite Rina Aninda Sidharta, Josua Sinambela, Medityas Winda Krissinta

Abstract


Diabetes Mellitus (DM) is a metabolic disease characterized by hyperglycemia due to abnormal secretions and/or insulin activity. Osteopontin (OPN) is an important component of inflammation and insulin resistance, and vitamin D decreases insulin resistance. This study aimed to analyze the correlation between OPN and glycemic control and total 25-OH vitamin D in type 2 DM. An observational analytic study with a cross-sectional approach was performed in Dr. Moewardi Hospital, Surakarta, from May to September 2018. Plasma OPN levels were measured by a sandwich enzyme immunoassay kit from Elabscience 96T Human OPN (USA), and a total of 25-OH vitamin D was evaluated using the ELFA method from Biomerieux SA (France). Data were tested by Pearson correlation (r). Type 2 DM subjects consisted of 45 (54.2%) males and 38 (45.8%) females, 36 (43.45%) well- and 47 (56.65%) poorly-controlled. The average age was 56.81±9.76 years old. The mean of OPN level in poorly-controlled cases was significantly higher (20.27±3.20 ng/mL) than well-controlled ones (15.04±3.34 ng/mL) with p=0.001. There was no significant difference in total 25-OH vitamin D between well- and poorly-controlled groups (19.84±6.65 vs. 17.24±6.78 ng/mL, respectively, p=0.085). The correlation of OPN with glycemic control (fasting glucose, 2-hour post-prandial glucose, HbA1c) and total 25-OH vitamin D in all subjects with type 2 DM were r=0.241 (p=0.028), r=0.378 (p=0.0001) r=0.529 (p=0.0001) and r=-0.151 (p=0.173), respectively. This study suggested that plasma OPN level was correlated with glycemic control but not with serum total 25-OH vitamin D in type 2 DM. Further research was needed in populations of other types of DM and other research variables related to inflammation or insulin resistance.


Keywords


Type 2 DM, osteopontin, total 25-OH vitamin D

Full Text:

PDF

References


American Diabetes Association (ADA). Standards of

medical care in diabetes-2018. Diabetes Care, 2018;

(1): S13-S27.

Perkeni. Pedoman pengelolaan dan pencegahan

diabetes melitus tipe 2 dewasa di Indonesia 2019.

Jakarta, PB Perkeni, 2019; 1-50.

Polonsky KS, Burant CF. Type 2 diabetes mellitus. In:

Melmed S, Polonsky KS, Larsen PR, Kronenberg HM.

th Williams textbook of endocrinology. 13 Ed.,

Philadelphia, Elsevier, 2016; 1386-1450.

Brownlee M, Aiello LP, Cooper ME, Vinik AI, Plutzky J,

Boulton AJM. Complications of diabetes mellitus. In:

Melmed S, Polonsky KS, Larsen PR, Kronenberg HM.

th Williams textbook of endocrinology. 13 Ed.,

Philadelphia, Elsevier, 2016; 1484-1581.

Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2

diabetes: A systematic review. Eur J Clin Nutr, 2011;

(9): 1005–1015.

Gravallese EM. Osteopontin: A bridge between bone

and the immune system. J. Clin. Invest, 2003; 112:

-149.

de Fusco C, Messina A, Monda V, Viggiano E,

Moscatelli F, et al. Osteopontin: Relation between

adipose tissue and bone homeostasis. Stem Cells

International, 2017; 2017: 1-6.

Sase SP, Ganu JV, Nagano N. Osteopontin: A novel

protein molecule. Indian Medical Gazette, 2012; 62-66.

Agah E, Zardui A, Saghazadeh A, Ahmadi M, Tafakhori

A, Rezaei N. Osteopontin (OPN) as a CSF and blood

biomarker for multiple sclerosis: A systematic review

and meta-analysis. PLoS One, 2018; 13(1): e0190252.

Van Driel M, Pols HAP, van Leeuwen JPTM. Osteoblast

differentiation and control by vitamin D and vitamin D

metabolites. Current Pharmaceutical Design, 2004;

(00): 1-21.

Al-qtaitat AI, Aldalaen SM. A review of non-collagenous

proteins; their role in bone. AJLS, 2014; 2(6): 351-355.

Thurner PJ, Chen CG, Lonova-Martin S, Sun L,

Harman A, et al. Osteopontin deficiency increases

bone fragility but preserves bone mass. Bone, 2010;

: 1564–1573.

Kahles F, Finfeisen HM, Bruemmer D. Osteopontin: A

novel regulator at the cross-roads of inflammation,

obesity, and diabetes. Molecular Metabolism, 2014; 3:

-393.

Musialik K, Skrypnik D, Dogdanski P, Szulinska M.

Osteopontin-a multifunctional protein and its impact

on an insulin resistance development. J Med Sci, 2014;

(83): 173-176.

Christakos S, Dhawan P, Verstuyf A, Verlinden L,

Carmeliet G. Vitamin D: Metabolism, molecular

mechanism of action, and pleiotropic effects. Physiol

Rev, 2016; 96: 365-408.

Gil A, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and

novel actions. Ann Nutr Metab, 2018; 72: 87-95.

Battault S, Whiting SJ, Peltier SL, Sadrin S, Gerber G,

Maixent JM. Vitamin D metabolism, functions and

needs: From science to health claims. Eur J Nutr, 2012;

(2): 1-14.

Boyraz I, Bilge U, Unalacak M, Bilgin M. A comparison

of 25(OH) vitamin D levels in patients with type 2

diabetes on oral hypoglycemic agents and insulin

treatment. Biomed Res, 2016; 27(1): 1-5.

Berezin AE, Kremzer AA. Circulating osteopontin as

a marker of early coronary vascular calcification in

type two diabetes mellitus patients with known

a s y m pto m a ti c coron a r y a rt e r y di s e a s e .

Atherosclerosis, 2013; 229: 475-481.

Chellaiah MA, Kizer N, Biswas R, Alvarez U,

Strauss-Schoenberger J, et al. Osteopontin deficiency

produces osteoclast dysfunction due to reduced CD44

surface expression. Mol. Biol. Cell, 2003; 14: 173-189.

Maser RE, Lenhard MJ, Pohlig RT, Balagopal PB.

Osteopontin and osteoprotegerin levels in type 2

diabetes and their association with autonomic function. J Diabetes Complications, 2016;

(3):507-510.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i2.1638

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.